Quintiles Establishes Bioanalytical Laboratory in Europe
News May 07, 2015
Quintiles has announced the expansion of its bioanalytical laboratory services with the establishment of a GLP-compliant bioanalytical liquid chromatography-mass spectrometry (LC-MS) laboratory.
The laboratory, which is located in Oss, the Netherlands, will have extensive bioanalytical testing capabilities and will provide a European facility for Quintiles customers to conduct pharmacokinetics studies.
The Oss laboratory facility combines a cohort of employees with extensive industry experience, automated processes, and a facility equipped to increase high-quality throughput. The new laboratory is led by Dr. Benno Ingelse, an industry expert with more than 15 years of (bio)analytical experience. In addition, the Oss laboratory will bolster and enhance Quintiles’ end-to-end clinical trial laboratory services.
“Adding this capability in Europe is a key step for our bioanalytical business and supports the strategy to increase our participation in the substantial European bioanalytical market,” said Costa Panagos, senior vice president and global head of Global Central Laboratories at Quintiles. “This is an exciting milestone for Quintiles and specifically our laboratory business as we expand our capabilities while continuing to provide the value and high-quality service our customers require.”
Currently, Quintiles’ bioanalytical and ADME capabilities and work are managed out of three laboratory sites in the U.S. The new laboratory will be fully integrated with Quintiles’ existing laboratory in Ithaca, New York, enabling the transfer of assays back and forth to accommodate global studies. The expansion of these services via the Oss laboratory boosts the depth and breadth of expertise that Quintiles provides to its customers, and further strengthens the global footprint of Quintiles’ laboratory business.
As part of Quintiles’ bioanalytical and ADME laboratory services group, the Oss lab would become part of the recently announced clinical trials laboratory services joint venture with Quest Diagnostics.
That transaction, which remains subject to regulatory approval and customary closing conditions, is anticipated to close in the third quarter of 2015. Until that transaction is completed, the Oss lab will continue to operate as part of Quintiles’ bioanalytical and ADME laboratory network.
“The Oss laboratory will further enhance the scale, clinical trial expertise and diverse therapeutic experience that will be a cornerstone of the proposed joint venture with Quest Diagnostics,” said Panagos, who will serve as the new joint venture’s CEO upon completion of the transaction. “The addition of the Oss laboratory is integral to the continued evolution of our laboratory business and we’re excited about the benefits it can provide as part of a globally scaled and agile business for our customers today as well as in the future.”
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019